Anthem Biosciences Limited · NSE:ANTHEM

Anthem Biosciences — Q3 FY2026 Earnings Presentation

13 slides from Anthem Biosciences's earnings presentation, Feb 5, 2026

  1. Slide 1: Stock exchange cover letter for earnings call presentation

    Date: February 05, 2026 To, BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Earnings Call Presentati

  2. Slide 2: Anthem Biosciences Limited Investor Presentation

    Anthem Biosciences Limited Investor Presentation February 05, 2026

  3. Slide 3: Safe Harbour

    Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "

  4. Slide 4: Consolidated Profit & Loss Statement: Q3FY26 vs Q3FY25 vs Q2FY26 Performance

    Consolidated Profit & Loss Statement: Q3FY26 vs Q3FY25 vs Q2FY26 Performance Particulars (₹ Mn) Q3FY26 Q3FY25 YoY Q2FY26 QoQ FY25 Revenue from Operations 4,232 4,978 -15.0% 5,500 -23.1% 18,446 CRDMO 3,332 4,135 -19.4% 4,719 -29.4% 15,061 Specialty Ingredients 899 843 6.7% 781 15.1% 3,385 Other Incom

  5. Slide 5: Consolidated Profit & Loss Statement: 9MFY26 vs 9MFY25 Performance

    Consolidated Profit & Loss Statement: 9MFY26 vs 9MFY25 Performance Particulars (₹ Mn) 9MFY26 9MFY25 YoY FY25 Revenue from Operations 15,134 13,614 11.2% 18,446 CRDMO 12,599 11,138 13.1% 15,061 Specialty Ingredients 2,535 2,475 2.5% 3,385 Other Income 1,046 717 45.9% 857 Total Revenues 16,180 14,330

  6. Slide 6: Q3FY26 Consolidated Financial Highlights

    Q3FY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 4,978 35.2% 41.8% 4,232 23.8% 20.3% 1,839 1,907 1,243 928 Q3FY25 Q3FY26 Q3FY25 Q3FY26 Q3FY25 Q3FY26 PBT after exceptional items2 (₹ Mn) Net Cash (₹ Mn) and PBT Margins

  7. Slide 7: 9MFY26 Consolidated Financial Highlights

    9MFY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 15,134 38.2% 41.5% 0.0% 25.7% 24.8% 40.0% 13,614 30.0% 20.0% 10.0% 0.0% 6,712 5,473 3,686 4,020 9MFY25 9MFY26 9MFY25 9MFY26 9MFY25 9MFY26 PBT after exceptional items2 (

  8. Slide 8: Margin profile continues to remain strong with a robust return profile for Q3FY26

    Margin profile continues to remain strong with a robust return profile for Q3FY26 ₹4,232 Mn 41.8% 20.3% Strong Business Q3FY26 Revenues Q3FY26 EBITDA Margin Q3FY26 PAT Margin Performance 2,228 / 1,097 400KL 142KL Robust Technology # Employees / Scientific Staff Custom Synthesis Capacity Fermentation

  9. Slide 9: 9MFY26 performance continues to be robust

    9MFY26 performance continues to be robust ₹15,134 Mn 41.5% 24.8% Strong Business 9MFY26 Revenues 9MFY26 EBITDA Margin 9MFY26 PAT Margin Performance 58.4% 14 10.5% Platforms across Commercial Molecules 9MFY26 R&D Services 9MFY26 Commercial Molecules discovery to Contribution to Revenues Contribution

  10. Slide 10: Financial Highlights: 9MFY26 and Q3FY26

    Financial Highlights: 9MFY26 and Q3FY26 Quarterly Performance:  Consolidated Revenue from Operations was ₹4,232 Mn for the quarter  CRDMO business delivered ₹3,332 Mn revenues  Specialty Ingredients delivered ₹899 Mn revenues  EBITDA was ₹1,907 Mn, with EBITDA margins at 41.8%  PAT (Profit Afte

  11. Slide 11: Financial Highlights: 9MFY26 and Q3FY26

    Financial Highlights: 9MFY26 and Q3FY26  Exceptional Items:  On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Co

  12. Slide 12: Message from Chairman, MD and CEO

    Message from Chairman, MD and CEO “Our 9MFY26 performance has shown steady progress in revenue terms and with improving margin profile our EBITDA has grown at 23% and PBT before exceptional items has grown around 20%. Our quarterly revenue performance was influenced by the higher base of the same qu

  13. Slide 13: Thank You

    Thank You Anthem Biosciences Limited NeoAnthem Lifesciences Private Limited Unit I: No.49, F1 &F2, Canara Bank Road, Unit III: 313-P,314-P, 318-P, Harohalli Bommasandra Industrial Area Phase 1, Industrial Area, Phase II, Bommasandra, Bangalore, 560 099, India Kanakapura Taluk, Ramnagar District, Har

Anthem Biosciences — Q3 FY2026 Earnings Presentation on 6ix